AMCURE

amcure leverages its in-depth knowledge of CD44 target biology to develop a novel therapeutic approach to treat metastatic squamous tumors. In cancer, blocking the extracellular target CD44v6 has a beneficial effect on several relevant receptor tyrosine kinase pathways. Our first-in-class CD44v6-inhibitor AMC303 entered clinical development in solid tumors in Q4 2016.

Also known as: amcure GmbH